FH基因缺失型肾细胞癌一例

FH-Deficient Renal Cell Carcinoma: a Case Report

  • 摘要: FH基因缺失型肾细胞癌(FH-deficient renal cell carcinoma, FH-dRCC)是一种罕见的、高侵袭性的肾细胞癌亚型。这种肿瘤常与遗传性平滑肌瘤病和肾细胞癌(hereditary leiomyomatosis and renal cell carcinoma,HLRCC)综合征相关,其发病机制涉及FH的双等位基因失活,导致富马酸盐积累,扰乱细胞代谢平衡和DNA处理过程,驱动致癌进程。本文报道了1例FH-dRCC患者,在接受根治性肾切除术后,短期出现复发及肝转移,随后接受了多线靶向及免疫联合治疗,患者病情曾一度获得影像学缓解,但最终出现广泛转移而去世。该病例提示FH-dRCC具有高度侵袭性、易早期复发转移,且对现有系统治疗的反应持续时间有限,临床需加强早期识别并积极探索更有效的联合治疗策略。

     

    Abstract: FH-deficient renal cell carcinoma(FH-dRCC) is a rare and highly aggressive subtype of renal cell carcinoma. This tumor is often associated with hereditary leiomyomatosis and renal cell carcinoma(HLRCC) syndrome. Its pathogenesis involves biallelic inactivation of the FH gene, leading to the accumulation of fumarate, which disrupts cellular metabolic balance and DNA repair processes, thereby driving tumorigenesis. This paper reports a patient with FH-dRCC. The patient underwent radical nephrectomy but experienced early postoperative recurrence and liver metastasis. Despite multiple lines of systemic therapy, including targeted and combination immunotherapy, which initially achieved radiographic response, the patient eventually died as the disease progressed with extensive metastases. This case highlights the highly aggressive nature of FH-dRCC, its propensity for early recurrence and metastasis, and the limited duration of response to current systemic therapies. There is a clinical need for enhanced early detection and active exploration of more effective combination treatment strategies.

     

/

返回文章
返回